Direct KRAS G12C inhibitors, sotorasib and adagrasib, received accelerated approval from the U.S. Food and Drug Administration (FDA) for previously treated advanced NSCLC patients with mKRAS G12C [24,25]. Here, KRAS is linked to non-small cell lung carcinoma.